CD270 | CAS# 104224-10-4

MedKoo Cat#: 412469 | Name: CD270

Description:

WARNING: This product is for research use only, not for human or veterinary use.

CD270 is a biochemical

Chemical Structure

CD270

CAS#104224-10-4

Theoretical Analysis

MedKoo Cat#: 412469

Name: CD270

CAS#: 104224-10-4

Chemical Formula: C23H24O2S

Exact Mass: 364.1497

Molecular Weight: 364.50

Elemental Analysis: C, 75.79; H, 6.64; O, 8.78; S, 8.80

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

CD 270; CD-270; CD270

IUPAC/Chemical Name

2-(5,5,8,8-tetramethyl-5,6,7,8-tetrahydronaphthalen-2-yl)benzo[b]thiophene-6-carboxylic acid

InChi Key

VYBLDUKQAWIMMM-UHFFFAOYSA-N

InChi Code

InChI=1S/C23H24O2S/c1-22(2)9-10-23(3,4)18-11-14(7-8-17(18)22)19-12-15-5-6-16(21(24)25)13-20(15)26-19/h5-8,11-13H,9-10H2,1-4H3,(H,24,25)

SMILES Code

CC1(CCC(C)(c2c1ccc(c(c3)sc4c3ccc(C(O)=O)c4)c2)C)C

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 364.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Matesanz-Isabel J, Sintes J, Llinàs L, de Salort J, Lázaro A, Engel P. New B-cell CD molecules. Immunol Lett. 2011 Jan 30;134(2):104-12. doi: 10.1016/j.imlet.2010.09.019. Epub 2010 Oct 7. PMID: 20933010. 2: Wang S, Ljubimov AV, Jin L, Pfeffer K, Kronenberg M, Ghiasi H. Herpes Simplex Virus 1 Latency and the Kinetics of Reactivation Are Regulated by a Complex Network of Interactions between the Herpesvirus Entry Mediator, Its Ligands (gD, BTLA, LIGHT, and CD160), and the Latency-Associated Transcript. J Virol. 2018 Nov 27;92(24):e01451-18. doi: 10.1128/JVI.01451-18. PMID: 30282707; PMCID: PMC6258941. 3: Llinàs L, Lázaro A, de Salort J, Matesanz-Isabel J, Sintes J, Engel P. Expression profiles of novel cell surface molecules on B-cell subsets and plasma cells as analyzed by flow cytometry. Immunol Lett. 2011 Jan 30;134(2):113-21. doi: 10.1016/j.imlet.2010.10.009. Epub 2010 Oct 15. PMID: 20951740. 4: Shui JW, Kronenberg M. HVEM: An unusual TNF receptor family member important for mucosal innate immune responses to microbes. Gut Microbes. 2013 Mar- Apr;4(2):146-51. doi: 10.4161/gmic.23443. Epub 2013 Jan 18. PMID: 23333859; PMCID: PMC3595075. 5: Shui JW, Kronenberg M. HVEM is a TNF Receptor with Multiple Regulatory Roles in the Mucosal Immune System. Immune Netw. 2014 Apr;14(2):67-72. doi: 10.4110/in.2014.14.2.67. Epub 2014 Apr 21. PMID: 24851095; PMCID: PMC4022780. 6: Ramos-Medina R, Montes-Moreno S, Maestre L, Cañamero M, Rodriguez-Pinilla M, Lázaro A, Roncador G. Immunohistochemical analysis of HLDA9 Workshop antibodies against cell-surface molecules in reactive and neoplastic lymphoid tissues. Immunol Lett. 2011 Jan 30;134(2):150-6. doi: 10.1016/j.imlet.2010.10.007. Epub 2010 Oct 12. PMID: 20946916. 7: Huang PY, Best OG, Almazi JG, Belov L, Davis ZA, Majid A, Dyer MJ, Pascovici D, Mulligan SP, Christopherson RI. Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia. Leuk Lymphoma. 2014 Sep;55(9):2085-92. doi: 10.3109/10428194.2013.867486. Epub 2014 Jan 24. PMID: 24289109. 8: Cabezón R, Sintes J, Llinàs L, Benitez-Ribas D. Analysis of HLDA9 mAbs on plasmacytoid dendritic cells. Immunol Lett. 2011 Jan 30;134(2):167-73. doi: 10.1016/j.imlet.2010.09.020. Epub 2010 Oct 7. PMID: 20933012. 9: Rodríguez-Bayona B, Ramos-Amaya A, Brieva JA. Differential expression of SLAMS and other modulatory molecules by human plasma cells during normal maturation. Immunol Lett. 2011 Jan 30;134(2):122-8. doi: 10.1016/j.imlet.2010.09.015. Epub 2010 Oct 13. PMID: 20923684. 10: Gazith J, Eustache J, Watts O, Cavey MT, Shroot B. An improved assay procedure and a new chemically stable ligand for cytosolic retinoic acid binding protein. Anal Biochem. 1988 Jun;171(2):238-47. doi: 10.1016/0003-2697(88)90481-2. PMID: 2841888.